"The research was funded by The Damon Runyon Cancer Research Foundation, the Cancer Research Institute and Merck. Celldex and Oncovir provided the materials for the clinical trial and the lab work."
That's where I first caught on to the Celldex Therapeutics. It's the final paragraph of this article:
According to the article the vaccine is based upon the antibody and immunotherapy field.
From the Celldex "Overview" on its website:
Celldex Therapeutics was founded based on a fundamental scientific belief that harnessing the power of immune system would break significant barriers in drug development for a variety of devastating diseases. Our scientific philosophy is derived from longstanding roots in the antibody and immunotherapy field that have led to breakthrough technologies both at Celldex and in previous companies, including Medarex (acquired by the Bristol-Myers Squibb Company), from which Celldex was spun out in 2005.
CLDX is trading at around $5 with a market cap of only $62 million. The reference to the company in the article is seems almost like an afterthought. But the potential of being even an "afterthought" partner in a cancer vaccine that may actually work seems to be worth a heck of a lot more than $62 million. The stock is trading about $1 off of its recent lows (up 24% on 5X its average volume on this news) so I would risk that $1.00 (stop) in hopes that the stock reaches into the double digits as the next study begins in March:
"Their results were successful enough to warrant another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer."
They are already expanding the trial to include other cancers.
What do they know?
BUY CLDX; Stop under $4.00